Allogene Therapeutics, INC Schedule 13G passive stakes

A Schedule 13G filing details beneficial ownership changes for Allogene Therapeutics, Inc. by key individuals and entities.

State Street Corporation has updated its beneficial ownership filing for Allogene Therapeutics Inc., reporting a 5.5% stake.

Citadel Advisors and Kenneth Griffin have filed a Schedule 13G reporting a combined beneficial ownership of 2.8% in Allogene Therapeutics, Inc.

Dr. Arie Belldegrun and affiliated entities have filed a Schedule 13G reporting a 5.4% beneficial ownership stake in Allogene Therapeutics, Inc.

Dr. David D. Chang and associated family trusts report a 4.9% beneficial ownership stake in Allogene Therapeutics, Inc.

Frazier Life Sciences entities filed a Schedule 13G reporting a combined beneficial ownership of approximately 4.7% in Allogene Therapeutics, Inc.

Dr. David D. Chang and affiliated trusts report a combined beneficial ownership of 5.2% in Allogene Therapeutics, Inc. common stock.

Dr. Arie Belldegrun and affiliated entities, including Vida Ventures, have filed an amended Schedule 13G disclosing their beneficial ownership of 5.6% of Allogene Therapeutics, Inc. common stock.

Capital World Investors has filed an amended Schedule 13G, indicating a 0.0% beneficial ownership in Allogene Therapeutics, Inc.

Dr. David D. Chang and affiliated trusts have updated their beneficial ownership in Allogene Therapeutics, Inc., now holding an aggregate of 4.9% of common stock.

Dr. Arie Belldegrun and affiliated entities report a combined beneficial ownership of 5.7% in Allogene Therapeutics, Inc. common stock.

Dr. David D. Chang and affiliated trusts updated their beneficial ownership in Allogene Therapeutics, Inc., collectively holding 5.0% of common stock.

Citadel Advisors LLC, Citadel Securities LLC, and Kenneth Griffin have disclosed beneficial ownership of Allogene Therapeutics, Inc. common stock, with Griffin holding a 6.1% stake.

Capital World Investors has filed a Schedule 13G, reporting a 5.6% beneficial ownership stake in Allogene Therapeutics, Inc. as of March 31, 2025.

Dr. David D. Chang, along with the Chang 2006 Family Trust, JEC 2019 Trust, and RTC 2019 Trust, has filed an amended Schedule 13G, reporting a combined beneficial ownership of 5.0% of Allogene Therapeutics, Inc.'s common stock as of March 31, 2025.

Dr. Arie Belldegrun and associated entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 12,543,444 shares, or 5.7%, of Allogene Therapeutics, Inc. common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% beneficial ownership stake in Allogene Therapeutics, Inc. as of March 31, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a beneficial ownership of 4.9% in Allogene Therapeutics Inc., signaling a reduction in their stake below the 5% reporting threshold.

Lynx1 Capital Management LP and Weston Nichols have jointly disclosed a beneficial ownership of 5.2% in Allogene Therapeutics, Inc., as of December 31, 2024.

Dr. Arie Belldegrun and several affiliated investment entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 5.8% of Allogene Therapeutics, Inc.'s common stock as of December 31, 2024.

Dr. David D. Chang, a key insider at Allogene Therapeutics, Inc., has filed an amended Schedule 13G disclosing a beneficial ownership of 5.1% of the company's common stock as of December 31, 2024.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, revealing a beneficial ownership of 11.3% of Allogene Therapeutics Inc.'s common stock as of December 31, 2024.